Will a reduction in community prescribing of quinolones decrease the prevalence of quinolone resistance?

Clinical Infectious Diseases

Volumn 49, Issue 6, 2009, Pages 876-877

  Davey, Peter ^a,c   Urquhart, Lynn ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c Mackenzie Building   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTHRAX; ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATION; ESCHERICHIA COLI; HUMAN; INFECTION PREVENTION; MATHEMATICAL MODEL; NONHUMAN; NOTE; PRESCRIPTION; PRIORITY JOURNAL; SEASONAL VARIATION; URINE CULTURE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI; HUMANS; PREVALENCE; QUINOLONES; RESEARCH DESIGN; SELECTION BIAS;

EID: 70049096588     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605531     Document Type: Note

References (20)

1. Boyd LB, Atmar RL, Randall GL, Hamill RJ, Steffen D, Zechiedrich L. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis 2008; 8:4.
2. Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol 2006;4:36-45.
3. Poirel L, Pitout JD, Calvo L, Rodriguez-Martinez JM, Church D, Nordmann P. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expandedspectrum beta-lactamase. Antimicrob Agents Chemother 2006;50:1525-7.
4. Steinke D, Davey PG. The association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies. Clin Infect Dis 2001; 33: S193-205.
5. Chung A, Perera R, Brueggemann AB, et al. Effect of antibiotic prescribing on antibiotic resistance in individual children in primary care: prospective cohort study. BMJ 2007; 335: 429.
6. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007; 369:482-90.
7. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A 1999;96:1152-6.
8. Levin BR. Minimizing potential resistance: a population dynamics view. Clin Infect Dis 2001;33(Suppl 3):S161-9.
9. Lipsitch M. The rise and fall of antimicrobial resistance. Trends Microbiol 2001;9:438-44.
10. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev 2005: CD003539.
11. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997;337:441-6.
12. Gottesman BS, Carmeli Y, Shitrit P, Chowers M. Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 2009;49:869-75 (in this issue).
13. Davey P, Brown E, Fenelon L, et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006; 12:211-6.
14. Cochrane Effective Practice and Organisation of Care Group. The data collection checklist. 2002:1-26. Available at: http://www.epoc.coch rane.org/Files/Website%20files/Documents/Re viewer%20Resources/ datacollectionchecklist .pdf Accessed 14 August 2009.
15. Donnan PT, Wei L, Steinke DT, et al. Presence of bacteriuria caused by trimethoprim resistant bacteria in patients prescribed antibiotics: multilevel model with practice and individual patient data. BMJ 2004;328:1297-300.
16. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. Clin Infect Dis 2001;33:1462-8.
17. Burnham KP, Anderson DR. Kullback-Leibler information as a basis for strong inference in ecological studies. Wildl Res 2001;28:111-9.
18. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N, Hughes D. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob Agents Chemother 2005;49:2343-51.
19. McGuire M, Keel A, Scott B. A revised framework for national surveillance of healthcare associated infection and the introduction of a new health efficiency and access to treatment (HEAT) target for Clostridium difficile associated disease (CDAD) for NHS Scotland. 2009. Available at: http://www.sehd.scot.nhs .uk/mels/CEL2009-ll.pdf. Accessed 11 June 2009.
20. Coenen S, Ferech M, Haaijer-Ruskamp FM, et al. European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. Qual Saf Health Care 2007; 16:440-5.